Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Search
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US
FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
More Green | Sustainable Development
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Transforming the Treatment of Lung Fibrosis through Lung Repair & Regeneration
Transforming the Treatment of Lung Fibrosis through Lung Repair & Regeneration
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Boehringer’s unique approach to innovation
Boehringer’s unique approach to driving patient-centric innovation
Partnering Days
Partnering Days
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
Romy's Third-generation Japanese American Journey
Romy's Third-generation Japanese American Journey
Contact Us
Contact Us
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
Our Commitment
Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Brigitte Fuhr
Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease